News articles about Zynerba Pharmaceuticals (NASDAQ:ZYNE) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zynerba Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.2748587380744 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Cannabis Stock News: Zynerba Reports Loss but Still Well Funded – PotNetwork (blog) (potnetwork.com)
- Lookout for these Two stocks: Keane Group, Inc. (NYSE:FRAC), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) – The Oracle Examiner (oracleexaminer.com)
- $-0.61 EPS Expected for Zynerba Pharmaceuticals, Inc. (ZYNE) – NMSU Hеrаld (nmsuherald.com)
- Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Operational Highlights – GlobeNewswire (press release) (globenewswire.com)
- Zynerba Pharmaceuticals (ZYNE) Posts Earnings Results (americanbankingnews.com)
A number of research analysts have recently weighed in on the company. Cantor Fitzgerald set a $20.00 price target on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Monday. HC Wainwright set a $23.00 price target on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday. Oppenheimer reissued a “hold” rating on shares of Zynerba Pharmaceuticals in a research note on Tuesday. Seaport Global Securities started coverage on Zynerba Pharmaceuticals in a research note on Friday, January 26th. They issued a “buy” rating and a $16.00 price target on the stock. Finally, Zacks Investment Research downgraded Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 18th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $17.77.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its quarterly earnings data on Monday, March 12th. The company reported ($0.60) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.60). During the same period last year, the company posted ($0.71) EPS. equities analysts forecast that Zynerba Pharmaceuticals will post -2.43 EPS for the current fiscal year.
In other Zynerba Pharmaceuticals news, major shareholder Michael Rapp acquired 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were acquired at an average price of $12.99 per share, with a total value of $194,850.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 9.91% of the company’s stock.
WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Zynerba Pharmaceuticals (ZYNE) Share Price” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://sportsperspectives.com/2018/03/14/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-zynerba-pharmaceuticals-zyne-share-price.html.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.